---
title: "LDN for Menopause: What Low‑Dose Naltrexone Is, What It Might Help, and What We Don’t Know"
description: "Low‑dose naltrexone (LDN) is an off‑label use of a medication originally developed to treat opioid and alcohol dependence. Some people use it in much smaller doses to target inflammation, immune regulation, chronic pain, and other symptoms that can overlap with the menopause transition."
url: "https://www.myalloy.com/blog/what-is-ldn-medication-and-does-it-work-for-menopause"
---

# LDN for Menopause: What Low‑Dose Naltrexone Is, What It Might Help, and What We Don’t Know

*Understanding the evidence, safety questions, and where LDN fits among menopause treatment options*

By Anna Johnson

## Summary

Low-dose naltrexone (LDN) is a prescription therapy that has received increasing attention in online menopause communities, where women often share personal experiences and discuss treatments that fall outside traditional menopause care.

Many women first hear about LDN while searching for relief from symptoms such as fatigue, sleep disruption, pain, or brain fog. Although LDN has been investigated for several other conditions, questions remain about whether those findings apply to menopause.

Understanding what LDN is, what research has shown, and how it compares with established menopause treatments can help women make informed decisions about their care.

[Start an Online Consult](https://secure.myalloy.com/experience?categories%5B%5D=mht&sku-ids%5B%5D=942fc36f-61c5-4cb9-ba30-8024ba2beb0a&skip-category-select=true&type=intake)

## What Is Low-Dose Naltrexone?

[Naltrexone](https://www.myalloy.com/solutions/oral-spironolactone) is an FDA-approved prescription medication that is typically used to help treat opioid and alcohol use disorders. It binds to opioid receptors in the body and blocks the effects of opioid medications. Regular prescription strength naltrexone is generally prescribed at 50mg for these purposes.

Low dose naltrexone, or LDN, refers to naltrexone given in much smaller doses, typically 1 to 4.5 mg, used off label to treat a variety of other conditions. Research looking at these lower doses has suggested that LDN may temporarily block opioid receptors while also influencing endorphin production and immune signaling. These mechanisms are still under investigation and have not been definitively proven at this time.

LDN is not a hormone therapy and is not FDA approved for the treatment of menopause symptoms,or any other medical condition.

## Why Is Low Dose Naltrexone (LDN) Being Discussed For Use In Menopause?

Women in perimenopause and menopause often experience fatigue, sleep disturbances, joint pain, mood changes, and difficulty concentrating. Several of these symptoms overlap with certain chronic conditions, including chronic fatigue syndrome, and some autoimmune disorders, where low dose naltrexone (LDN) has been explored as a potential treatment. As a result, women experiencing menopause symptoms may encounter discussions about LDN while searching for additional treatment options for their symptoms.

Although this symptom overlap helps explain why LDN has become part of menopause conversations, it should not be interpreted as evidence that the medication treats menopause itself.

> “There are so many FDA approved hormonal and non-hormonal treatment options available now for our patients having menopausal symptoms, that an unregulated, unproven treatment should rarely ever be needed,”according to Dr Traci Kurtzer, a board-certified obstetrician-gynecologist with over 30 years of clinical experience.

## What Does Research Show About Low Dose Naltrexone (LDN) in Menopause?

At present, there are no clinical trials that evaluate low-dose naltrexone for use in the treatment of menopause symptoms such as hot flashes, sleep disturbances, mood changes, or cognitive symptoms. 

Studies that do investigate low dose naltrexone for other conditions provide useful background information about how it might work, but the data cannot be assumed to apply to menopause because the underlying conditions and treatment goals differ.

Additional research is needed before the role of LDN in menopause management can be determined. At this time, LDN is not FDA approved or recommended in major menopause treatment guidelines for the management of menopause symptoms. 

## Risks of Low Dose Naltrexone (LDN)

LDN has no accepted clinical guidelines and when it is used it is prescribed “off label.” This means there are no established recommendations for dosing or monitoring LDN for menopause, and prescribing practices may vary among clinicians. 

Commonly reported side effects of LDN include vivid dreams, sleep disturbances, headache, and gastrointestinal symptoms, although it is reported that some people tolerate the treatment well.

Naltrexone is designed to block opioid receptors and can interfere with the effects of opioid pain medications. These medications should not generally be used together unless specifically directed by a healthcare professional. 

Anyone considering LDN should review their medications, medical history, and treatment goals with a healthcare professional before starting therapy.

## What Treatments Have Stronger Evidence for Menopause Symptoms?

For women seeking treatment for bothersome menopause symptoms, several therapies have much stronger clinical evidence than LDN. 

Hormone replacement therapy (HRT) remains the most effective treatment for many of the most disruptive symptoms of menopause, including hot flashes and night sweats,  in women who are appropriate candidates. There are also several FDA-approved nonhormonal medications available.

The most appropriate treatment depends on a woman's symptoms, medical history, and personal preferences rather than a single medication being suitable for everyone.

[Start Your HRT Consult](https://secure.myalloy.com/experience?categories%5B%5D=mht&sku-ids%5B%5D=942fc36f-61c5-4cb9-ba30-8024ba2beb0a&skip-category-select=true&type=intake)

## In Summary

LDN is an off-label medication that has generated growing interest among women navigating menopause. However, direct research evaluating LDN for menopause symptoms remains very limited, and existing studies do not establish its effectiveness for this purpose. While future research may provide additional answers, evidence-based menopause therapies continue to have the strongest support for treating many common symptoms.

Women who are curious about LDN should discuss both established and emerging treatment options with a menopause-specialized clinician to determine which approach might be best for them.

---

## Frequently Asked Questions

### Is Low-Dose Naltrexone (LDN) FDA-approved for treating menopause?

Low-Dose Naltrexone (LDN) refers to naltrexone administered in small doses (typically 1 to 4.5 mg) rather than the standard 50 mg dose used for opioid and alcohol use disorders. LDN is prescribed off-label and is not FDA-approved to treat menopause symptoms, hormone therapy, or any other medical condition. 

### Does research support using Low-Dose Naltrexone for menopause symptoms?

No, there are currently no clinical trials evaluating LDN for treating menopause symptoms such as hot flashes, sleep disturbances, mood changes, or cognitive issues. Direct research does not establish its effectiveness for menopause, and it is not recommended by major menopause treatment guidelines. Therapies such as hormone replacement therapy (HRT) and FDA-approved nonhormonal medications have significantly stronger clinical evidence. 

### What are the side effects and risks of taking Low-Dose Naltrexone?

Because LDN is used off-label for menopause, there are no established dosing or monitoring guidelines. Reported side effects include vivid dreams, sleep disturbances, headaches, and gastrointestinal symptoms. Additionally, because naltrexone blocks opioid receptors, it can interfere with opioid pain medications and should generally not be combined with them unless specifically directed by a healthcare provider. 

---

## References

1. Cucinelli F, Soranna L, Perri C, Barini A, Cento RM, Mancuso S, Lanzone A. Use of naltrexone in postmenopausal women with exaggerated insulin secretion: a pilot study. Fertil Steril. 2004 Apr;81(4):1047-54. doi: 10.1016/j.fertnstert.2003.05.036. PMID: 15066462. 
2. Guido M, Romualdi D, Lanzone A. Role of opioid antagonists in the treatment of women with glucoregulation abnormalities. Curr Pharm Des. 2006;12(8):1001-12. doi: 10.2174/138161206776055895. PMID: 16533167. 
3. Laatikainen TJ. Corticotropin-releasing hormone and opioid peptides in reproduction and stress. *Ann Med.* 1991;23(5):489-496. doi:10.3109/07853899109148066
4. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. *Menopause.* 2022;29(7):767-794. doi:10.1097/GME.0000000000002028
5. American College of Obstetricians and Gynecologists. Hormone Therapy for Menopause. ACOG. Reaffirmed 2024. Accessed July 21, 2026.
6. DailyMed. Naltrexone hydrochloride tablets. National Library of Medicine. Updated June 2024. Accessed July 21, 2026.
7. US Food and Drug Administration. FDA-approved drugs: Naltrexone hydrochloride. US Food and Drug Administration. Accessed July 21, 2026.

## Related Content

1. [https://www.myalloy.com/blog/low-dose-birth-control-menopause-symptoms](https://www.myalloy.com/blog/low-dose-birth-control-menopause-symptoms)
2. [https://www.myalloy.com/blog/menopause-is-different-for-black-women-we-talked-about-it](https://www.myalloy.com/blog/menopause-is-different-for-black-women-we-talked-about-it)
3. [https://www.myalloy.com/blog/dr-sharon-malone-great-big-news-in-the-menopause-world](https://www.myalloy.com/blog/dr-sharon-malone-great-big-news-in-the-menopause-world)
4. [https://www.myalloy.com/solutions/low-dose-birth-control-pill](https://www.myalloy.com/solutions/low-dose-birth-control-pill)
5. [https://www.myalloy.com/solutions](https://www.myalloy.com/solutions)
6. [https://www.myalloy.com/science/menopause](https://www.myalloy.com/science/menopause)
7. [https://www.myalloy.com/blog/why-is-estrogen-important-menopause](https://www.myalloy.com/blog/why-is-estrogen-important-menopause)
8. [https://www.myalloy.com/blog/hormone-therapy-101-with-dr-corinne-menn](https://www.myalloy.com/blog/hormone-therapy-101-with-dr-corinne-menn)
9. [https://www.myalloy.com/blog/im-in-my-40s-and-am-having-irregular-periods-am-i-in-perimenopause](https://www.myalloy.com/blog/im-in-my-40s-and-am-having-irregular-periods-am-i-in-perimenopause)
10. [https://myalloy.zendesk.com/hc/en-us/articles/29985630231443-Do-I-need-a-mammogram](https://myalloy.zendesk.com/hc/en-us/articles/29985630231443-Do-I-need-a-mammogram)
11. [https://myalloy.zendesk.com/hc/en-us/articles/30013422096147-Can-I-still-be-treated-if-I-do-not-have-a-uterus](https://myalloy.zendesk.com/hc/en-us/articles/30013422096147-Can-I-still-be-treated-if-I-do-not-have-a-uterus)
12. [https://myalloy.zendesk.com/hc/en-us/articles/28263366988307-Does-Alloy-offer-Testosterone](https://myalloy.zendesk.com/hc/en-us/articles/28263366988307-Does-Alloy-offer-Testosterone)
13. [https://myalloy.zendesk.com/hc/en-us/articles/25033598566035-How-does-Alloy-work](https://myalloy.zendesk.com/hc/en-us/articles/25033598566035-How-does-Alloy-work)
14. [https://myalloy.zendesk.com/hc/en-us/articles/39471023349523-Can-I-take-GLP-1-medication-with-Menopausal-Hormone-Therapy-MHT](https://myalloy.zendesk.com/hc/en-us/articles/39471023349523-Can-I-take-GLP-1-medication-with-Menopausal-Hormone-Therapy-MHT)

## Citations

1. Francesco Cucinelli, Liberato Soranna, Concetta Perri, Angela Barini, Rosa Maria Cento, Salvatore Mancuso, et al.. Use of naltrexone in postmenopausal women with exaggerated insulin secretion: a pilot study. Fertil Steril 2004;81(4):1047-54. PMID:15066462. — [View source](https://linkinghub.elsevier.com/retrieve/pii/S001502820400007X)
2. M Guido, D Romualdi, A Lanzone. Role of opioid antagonists in the treatment of women with glucoregulation abnormalities. Curr Pharm Des 2006;12(8):1001-12. PMID:16533167. — [View source](https://www.eurekaselect.com/56000/article)
3. Allyssa J Allen, James A McCubbin, James P Loveless, Suzanne G Helfer. Effects of estrogen and opioid blockade on blood pressure reactivity to stress in postmenopausal women. J Behav Med 2014;37(1):94-101. PMID:23135529. — [View source](https://doi.org/10.1007/s10865-012-9468-3)
4. T J Laatikainen. Corticotropin-releasing hormone and opioid peptides in reproduction and stress. Ann Med 1991;23(5):489-96. PMID:1756018. — [View source](https://www.tandfonline.com/doi/10.3109/07853899109150508)

---

*This is a markdown version of [https://www.myalloy.com/blog/what-is-ldn-medication-and-does-it-work-for-menopause](https://www.myalloy.com/blog/what-is-ldn-medication-and-does-it-work-for-menopause) for AI/LLM consumption.*